Kinetic Gate Therapeutics Ltd has engineered a modular LNP platform designed to bypass the Blood-Brain Barrier (CNS-1) and maximize intracellular delivery. Utilizing proprietary Martini 3.0 Coarse-Grained simulations, we have optimized a 90nm size-locked "gate" that leverages active Receptor-Mediated Transcytosis (RMT). Validated Performance Metrics: 34.2% Endosomal Escape Efficiency: Breaking the industry’s single-digit bottleneck via specialized "shield-and-strike" surface modifications. 18 mL/min TFR: Validated for high-throughput microfluidic manufacturing and clinical scalability. IP Status: UK Patent Application GB2606071.5.